Phase III Hallmark QUAD: ASV+DCV+Peg+Rib (Nulls/Partials)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy, as determined by the proportion of subjects
with Sustained Virologic Response at Post-Treatment Week 12 (SVR12), defined as Hepatitis C
virus (HCV) Ribonucleic acid (RNA) < Limit of quantitation (LOQ) at post-treatment Week 12.